259
release kinetics. Indeed, less than 10% of the loaded amount of
drug was released during the first 2 h [2].
Meloxicam is a nonsteroidal anti-inflammatory drug that acts
by inhibiting the synthesis of prostaglandins and has a limited
aqueous solubility of 9.4 μg/mL useful for therapeutic intervention
in the management of neurogenic and inflammatory pain [57].
Inclusion complexes of meloxicam with β-cyclodextrin and
β-cyclodextrin-based pyromellitic nanosponges were prepared to
enhance the solubility and stability of meloxicam and prolong its
release using different methods:
– Physical mixing (P): β-Cyclodextrin and meloxicam complexes
were prepared at a molar ratio of 1:1 via trituration at ambient
temperature for 30 min.
– Kneading (K): β-Cyclodextrin and meloxicam were triturated
in an equimolar ratio (1:1) in the presence of PEG 400 continually kneaded for 30 min and then dried at room
temperature.
– Sonication (N): Meloxicam was added to a dispersion of nanosponges in DCM at a ratio of 1:1 (w/w) and then sonicated
for 24 h at room temperature.
The encapsulation efficiencies of the methods were found to
follow the order: P < K < N. The effective encapsulation of meloxicam in β-CD and in the β-CD NSs might have been due to the van
der Waals force of attraction between the aromatic ring protons of
the drug and the inner protons of β-CD [58].
Viral diseases affect billions of people each year worldwide causing
millions of deaths. Despite the accumulation of a large body of
knowledge about the replicative and pathogenetic mechanisms of
many human viral pathogens, approved antiviral drugs are available
2.3 Cyclodextrin
Nanosponges
for Antiviral Drugs
Fig. 3 Effect of the increasing amount of cross-linker with respect to CD (expressed here as mol of cross-linker
per mol of CD) on CDNS structure. The cross-linking degree increased up to 1:6; then further excess of EDTA
causes branching of CD units rather than further cross-linking [3]
Drug-Encapsulated Cyclodextrin Nanosponges
release kinetics. Indeed, less than 10% of the loaded amount of
drug was released during the first 2 h [2].
Meloxicam is a nonsteroidal anti-inflammatory drug that acts
by inhibiting the synthesis of prostaglandins and has a limited
aqueous solubility of 9.4 μg/mL useful for therapeutic intervention
in the management of neurogenic and inflammatory pain [57].
Inclusion complexes of meloxicam with β-cyclodextrin and
β-cyclodextrin-based pyromellitic nanosponges were prepared to
enhance the solubility and stability of meloxicam and prolong its
release using different methods:
– Physical mixing (P): β-Cyclodextrin and meloxicam complexes
were prepared at a molar ratio of 1:1 via trituration at ambient
temperature for 30 min.
– Kneading (K): β-Cyclodextrin and meloxicam were triturated
in an equimolar ratio (1:1) in the presence of PEG 400 continually kneaded for 30 min and then dried at room
temperature.
– Sonication (N): Meloxicam was added to a dispersion of nanosponges in DCM at a ratio of 1:1 (w/w) and then sonicated
for 24 h at room temperature.
The encapsulation efficiencies of the methods were found to
follow the order: P < K < N. The effective encapsulation of meloxicam in β-CD and in the β-CD NSs might have been due to the van
der Waals force of attraction between the aromatic ring protons of
the drug and the inner protons of β-CD [58].
Viral diseases affect billions of people each year worldwide causing
millions of deaths. Despite the accumulation of a large body of
knowledge about the replicative and pathogenetic mechanisms of
many human viral pathogens, approved antiviral drugs are available
2.3 Cyclodextrin
Nanosponges
for Antiviral Drugs
Fig. 3 Effect of the increasing amount of cross-linker with respect to CD (expressed here as mol of cross-linker
per mol of CD) on CDNS structure. The cross-linking degree increased up to 1:6; then further excess of EDTA
causes branching of CD units rather than further cross-linking [3]
Drug-Encapsulated Cyclodextrin Nanosponges